Aurobindo Pharma is currently trading at Rs. 1145.20, up by 16.55 points or 1.47% from its previous closing of Rs. 1128.65 on the BSE.
The scrip opened at Rs. 1126.40 and has touched a high and low of Rs. 1146.95 and Rs. 1118.60 respectively. So far 6564 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 581.50 on 19-May-2023.
Last one week high and low of the scrip stood at Rs. 1171.50 and Rs. 1097.50 respectively. The current market cap of the company is Rs. 66131.96 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.30% and 6.87% respectively.
The United States Food and Drug Administration (US FDA) has completed the inspection at Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma’s Unit-VII, an API manufacturing facility, situated at Parwada Mandal, Anakapally District, Andhra Pradesh from May 5 to May 10, 2024. The inspection closed with 1 observation. The observation is of procedural in nature and will be responded to within the stipulated time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: